Search

EVIDENCE-BASED

Breakthroughs

EVIDENCE-
BASED

Breakthroughs

Transforming vascular care based on evidence-based decisions means utilizing clinical data that meets the highest standards. Robust clinical evidence program to establish new standards to transform vascular care. International, randomized, multi-center studies serve as the foundation for disruptive innovation.

Landmark BIOADAPTOR RCT

DynamX coronary bioadaptor is first device with RCT data demonstrating significantly better effectiveness in early return of vessel function and stabilization of plaques vs. state-of-the-art drug-eluting stent, the Resolute Onyx™ DES.

The BIOADAPTOR RCT is an international, single-blinded, randomized controlled (1:1) trial comparing a sirolimus-eluting bioadaptor with a contemporary zotarolimus-eluting stent in 445 patients. Both arms had large randomized multi-imaging modality subgroups of 100 patients powered to document standard stent effectiveness benchmarks, and the new effectiveness benchmarks of vessel motion and function. Data collection will continue through five years.

Study Design:
  • 445 patients enrolled
  • 1:1 randomization versus Resolute Onyx DES
  • Primary endpoint: TLF at 12 months (powered for non-inferiority)
  • Secondary endpoints: Imaging by QCA/IVUS/OCT at 12 months
  • Clinical follow-up to 5 years
Key Findings:

The clinical trial met its primary endpoint of Target Lesion Failure (TLF) non-inferiority at 12 months. The novel DynamX coronary bioadaptor achieved a very low 1.8% TLF rate compared to 2.8% for Resolute Onyx DES (p<0.001), as well as similar acute performance, acute lumen gain, and percent diameter stenosis at baseline. Two-year results show that the TLF curves of the BIOADAPTOR RCT diverge further after the 1-year follow-up in favor of DynamX, with significant difference in TLF and Target Vessel Failure (TVF) rates favoring the bioadaptor over DES.

And, for the first time seen in a coronary revascularization implant, the bioadaptor demonstrated normal pulsatility in the device treated segment as well as novel findings of plaque stabilization and regression, confirming restoration of vessel function at 12 months.

With pulsatility restored, more blood is able to flow with every heartbeat, bringing more oxygen deeper into the heart and helping alleviate symptoms associated with Coronary Artery Disease.

0 %

Primary endpoint: target lesion failure at 12 months vs. 2.8% for Resolute Onyx™ (p < 0.001)

0 %

Increase in blood flow with every heartbeat, as pulsatility returns

0 %

Plaque volume regression in lipid rich lesions vs. +10% for DES (p = 0.008)

Significant TLF reduction driven by lower CVD, TVMI, TLR

INFINITY-SWEDEHEART Clinical Trial

The INFINITY-SWEDEHEART study evaluates the safety and effectiveness of the DynamX coronary bioadaptor, the first metallic coronary artery implant that adapts to vessel physiology, compared to the Resolute Onyx drug-eluting stent, in the treatment of patients with ischemic heart disease with de novo native coronary artery lesions in epicardial vessels.

It is the largest randomized trial of the DynamX coronary bioadaptor to date with 2,400 patients enrolled, covering a real-world population.

Study Design:
  • Interventional Clinical Trial
  • 2400 participants enrolled in Sweden
  • Ages 18 – 85 years
  • 1:1 randomization of eligible patients with DynamX : Resolute Onyx
  • Intervention Model: Parallel Assignment
Primary Endpoint(s):
  • Primary Device Oriented Clinical Endpoint is target lesion failure (TLF); a composite of cardiovascular death, target vessel myocardial infarction (TV-MI), or ischemia-driven target lesion revascularization (ID-TLR).

Secondary Endpoints:
  • Device Success (Lesion Level Analysis)
  • Procedural Success (Patient Level Analysis)

DynamX Mechanistic Clinical Study

DynamX coronary bioadaptor demonstrated very good 36-month clinical outcomes, highlighted by the absence of target-vessel myocardial infarction and definite or probable device thrombosis, and only one target lesion revascularization up to 36 months.

Study Design:
  • Multi-center, single-arm, mechanistic clinical study
  • 50 patients at 7 international sites
  • Treatment of single, de novo lesions
  • Followed out to 30 days, 9 and 12 months, 2 and 3 years
Key Findings:
  • Positive vascular remodeling demonstrated by a vessel area increase of 3% and a device area increase of 5%
  • Cyclic pulsatility demonstrated by OCT with a difference in cross-sectional lumen area of 11% between systole and diastole
  • 4 TLF out to 36 months: 3 deaths – investigational sites reported all as unrelated to device or procedure; only 1 clinically driven TLR
  • Zero incidence of definite or probable device thrombosis

DESyne BDS Plus RCT

The DESyne BDS Plus Randomized Clinical Trial (RCT) is a prospective, multicenter, single-blind study evaluating the safety, effectiveness, and performance of world’s first triple-drug site-specific antithrombotic therapy (TRx) compared to DESyne X2 Drug-Eluting Coronary Stent System in the treatment of de novo native coronary artery lesions. The trial includes 202 patients across 14 sites in Europe, New Zealand and Brazil. An imaging subset of 58 patients had angiographic and optical coherence tomography (OCT) assessment completed in the first six months. Data collection will continue through three years.

Study Design:
  • Prospective, multicenter, randomized
  • 202 patients
  • 60 patient imaging subset
  • 14 sites
  • Primary endpoint of TLF at 3 days or through hospital discharge
  • Secondary endpoint of LLL at 6 months
Key Findings:

12-month results from DESyne BDS Plus RCT demonstrate the safety and effectiveness of site specific anti-thrombotic drug therapy

  • No CVD, TV-MI, or stent thrombosis (definite/probable)
  • Significantly lower TLF rate (2.1% vs. 9.3%, p=0.030) and TVF rate (2.1% vs. 10.3%, p=0.017) than the contemporary DES group in complex patients
  • Drug pharmacokinetics results showed systemic subtherapeutic levels of the two anticoagulants through 7 days while maintaining therapeutic effect at the site of implant through 6 months

PINNACLE I Study for Intravascular Hertz Contact Lithotripsy

The PINNACLE I clinical study assesses the safety and performance of the LithiX Coronary Hertz Contact Intravascular Lithotripsy catheter to treat moderately to severely calcified coronary artery lesions by calcium fragmentation utilizing Hertz contact stress LithiX HC-IVL catheter.

Study Design:
  • Multi-center, prospective, non-randomized, single arm
  • Up to 60 patients
  • 30 patients OCT imaging subgroup
  • Primary Safety: MACE within 30 days (cardiac death, MI and TVR)
  • Primary Efficacy: Clinical success defined as residual stenosis <50% after stenting with no evidence of in-hospital MACE
  • Follow-up 30 days, 6 months
Key Findings:

PINNNACLE I outcomes demonstrated the safety and effectiveness of LithiX Hertz Contact IVL with short procedure time and short learning curve

  • Primary safety and efficacy endpoint met and residual stenosis <30% with no in-hospital MACE through discharge in 98.3% of patients
  • Zero final angiographic complications and low MACE (1.7%) through 30-day follow up
  • Acute gain of 1.60mm ± 0.48 final post-stent
  • % diameter stenosis of 12.5% ± 4.5 final post-stent
  • Procedure time of 59.5 minutes (40.5, 76.0)a

OCT imaging subgroup (N = 32; L = 32b)

  • Maximum continuous calcium arc of 263.4⁰ ± 77.1
  • 31% presence of calcified nodules
  • Optimal stent expansion of 100.9%, 103.4% and 96.7% at minimum lumen area (MLA), maximum calcium site (MCS), and minimum stent area (MSA), respectively
  • 90.6% lesions with calcium fracture and 75.0% lesions with 2 or more calcium fractures
  • Deep average fracture depth of 0.81mm ± 0.33 and fracture width 0.66mm ± 0.29

OCT Imaging Confirmed High Fracture Depth and Width Even in Complex Calcified Lesions

Calcium score 4
EXR_Clinical Evidence_Calcium Score 4_1
EXR_Clinical Evidence_Calcium Score 4_2
Calcium score 2, Nodule Present
EXR_Clinical Evidence_Calcium Score 2_1
EXR_Clinical Evidence_Calcium Score 2_2

Note: aMedian (interquartile range). bSubject has two target lesions with OCT analysis on one target lesion only.

PMN 1710 Rev C